drugset / Trial / NCT02564497

A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C

NCT02564497

Phase 1 Completed 491 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects

Timeline

Start
2015-10-02
Primary completion
2017-01-27
Completion
2017-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Belatacept Protein / enzyme biologic

Indications

No indication recorded.